6628 Stock Overview
Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs in the People’s Republic of China and the United States.
Transcenta Holding Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$3.75|
|52 Week High||HK$16.18|
|52 Week Low||HK$3.72|
|1 Month Change||-16.85%|
|3 Month Change||-25.00%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-71.68%|
Recent News & Updates
|6628||HK Biotechs||HK Market|
Return vs Industry: Insufficient data to determine how 6628 performed against the Hong Kong Biotechs industry.
Return vs Market: Insufficient data to determine how 6628 performed against the Hong Kong Market.
|6628 Average Weekly Movement||6.5%|
|Biotechs Industry Average Movement||7.9%|
|Market Average Movement||6.5%|
|10% most volatile stocks in HK Market||12.8%|
|10% least volatile stocks in HK Market||3.1%|
Stable Share Price: 6628 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 6628's weekly volatility (6%) has been stable over the past year.
About the Company
Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs in the People’s Republic of China and the United States. The company develops MSB2311, a humanized PD-L1 monoclonal antibody (mAb) candidate for TMB-H solid tumors; TST001, a humanized claudin 18.2 mAb candidate for solid tumors, such as gastric cancer and is under Phase II clinical trial; TST005, a PD-L1/TGF-ß bi-functional antibody candidate which is under Phase Ia clinical trial for solid tumors, including certain lung cancers; TST010, an antibody candidate targeting regulatory T cells to enhance T cell mediated tumor killing;TST002 (Blosozumab), a humanized sclerostin mAb candidate for osteoporosis; and TST004, a humanized mannan-binding lectin serine protease 2 (MASP 2) mAb candidate for IgA kidney diseases. It also develops TST003, an antibody candidate targeting a novel immune regulatory protein produced by tumor-associated fibroblasts or tumor cells with mesenchymal phenotype; TST006, a bi-specific claudin 18.2/PD-L1 antibody; TST008, a tri-functional antibody combining a MASP2 antibody fused with a truncated transmembrane activator and CAML interactor protein; MSB0254, a humanized VEGFR-2 mAb candidate for solid tumors and is under Phase Ib/IIa clinical trials; and MSB2311, A humanized PD-L1 mAb Candidate for solid tumors and is under Phase Ib/IIa clinical trials Transcenta Holding Limited has collaboration agreements with Eli Lilly and Company, Alebund Pharmaceuticals, and Merck.
Transcenta Holding Fundamentals Summary
|6628 fundamental statistics|
Is 6628 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|6628 income statement (TTM)|
|Cost of Revenue||CN¥40.87m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-3.85|
|Net Profit Margin||-3,414.56%|
How did 6628 perform over the long term?See historical performance and comparison
Is 6628 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6628?
Other financial metrics that can be useful for relative valuation.
|What is 6628's n/a Ratio?|
Price to Sales Ratio vs Peers
How does 6628's PS Ratio compare to its peers?
|6628 PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
1061 Essex Bio-Technology
1228 CANbridge Pharmaceuticals
1875 TOT BIOPHARM International
6628 Transcenta Holding
Price-To-Sales vs Peers: 6628 is expensive based on its Price-To-Sales Ratio (28.6x) compared to the peer average (21.4x).
Price to Earnings Ratio vs Industry
How does 6628's PE Ratio compare vs other companies in the HK Biotechs Industry?
Price-To-Sales vs Industry: 6628 is expensive based on its Price-To-Sales Ratio (28.6x) compared to the Hong Kong Biotechs industry average (27.4x)
Price to Sales Ratio vs Fair Ratio
What is 6628's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||28.6x|
|Fair PS Ratio||2.5x|
Price-To-Sales vs Fair Ratio: 6628 is expensive based on its Price-To-Sales Ratio (28.6x) compared to the estimated Fair Price-To-Sales Ratio (2.5x).
Share Price vs Fair Value
What is the Fair Price of 6628 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 6628's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 6628's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
How is Transcenta Holding forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6628 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 6628 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 6628 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 6628's revenue (17.8% per year) is forecast to grow faster than the Hong Kong market (10% per year).
High Growth Revenue: 6628's revenue (17.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6628 is forecast to be unprofitable in 3 years.
Discover growth companies
How has Transcenta Holding performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: 6628 is currently unprofitable.
Growing Profit Margin: 6628 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 6628's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 6628's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6628 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (9.3%).
Return on Equity
High ROE: 6628 has a negative Return on Equity (-87.28%), as it is currently unprofitable.
Discover strong past performing companies
How is Transcenta Holding's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: 6628's short term assets (CN¥1.4B) exceed its short term liabilities (CN¥425.8M).
Long Term Liabilities: 6628's short term assets (CN¥1.4B) exceed its long term liabilities (CN¥153.6M).
Debt to Equity History and Analysis
Debt Level: 6628 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 6628's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6628 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 6628 has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 3.9% each year.
Discover healthy companies
What is Transcenta Holding current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 6628's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 6628's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 6628's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6628's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 6628 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Xueming Qian (53 yo)
Dr. Xueming Qian, Ph.D. has been Chief Executive Officer and Executive Director at Transcenta Holding Limited. He was the Founder, Chairman and Chief Executive Officer of MabSpace Biosciences Co., Ltd. Dr....
CEO Compensation Analysis
Compensation vs Market: Xueming's total compensation ($USD767.13K) is above average for companies of similar size in the Hong Kong market ($USD305.74K).
Compensation vs Earnings: Xueming's compensation has been consistent with company performance over the past year.
Experienced Management: 6628's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Experienced Board: 6628's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 6628 insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: 6628 only recently listed within the past 12 months.
Transcenta Holding Limited's employee growth, exchange listings and data sources
- Name: Transcenta Holding Limited
- Ticker: 6628
- Exchange: SEHK
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: HK$1.670b
- Shares outstanding: 445.33m
- Website: https://www.transcenta.com
Number of Employees
- Transcenta Holding Limited
- B6-501, 218 Xinghu Street
- Jiangsu Province
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/11 00:00|
|End of Day Share Price||2022/08/11 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.